Evidence map›Paper›PMID 34344210›Full record

ArticleInternational journal of immunopathology and pharmacology

Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression.

Jie Wang, Ke-Yong Tian, Ying Fang, Hui-Min Chang, Ya-Nan Han, Fu-Quan Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Extracellular vesicles for developing targeted hearing loss therapy.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jie WangDepartment of Otolaryngology-Head and Neck Surgery, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.
Ke-Yong TianDepartment of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Xi'an, China.
Ying FangDepartment of Otolaryngology-Head and Neck Surgery, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.
Hui-Min ChangDepartment of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Xi'an, China.
Ya-Nan HanDepartment of Otolaryngology-Head and Neck Surgery, The Affiliated Children Hospital of Xi'an Jiaotong University, Xi'an, China.
Fu-Quan ChenDepartment of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Xi'an, China.ORCID https://orcid.org/0000-0002-4625-073X
Xi’an Children’s Hospital · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCruciferous vegetables are a rich source of sulforaphane (SFN), which acts as a natural HDAC inhibitor (HDACi). Our previous study found that HDACi could restore histone acetyltransferase/histone deacetylase (HAT/HDAC) balance in the cochlea and attenuate gentamicin-induced hearing loss in guinea pigs. Here, we investigated the protective effect of SFN on cisplatin-induced hearing loss (CIHL).

methodsThirty rats were randomly divided into 3 equal groups: the control group, cisplatin group, and SFN+cisplatin group. Rats were injected with SFN (30 mg/kg once a day) and cisplatin (7 mg/kg twice a day) for 7 days to investigate the protective role of SFN on CIHL. We observed auditory brainstem response (ABR) threshold shifts and immunostained cochlear basilar membranes of rats. For in vitro experiments, we treated HEI-OC1 cells and rat cochlear organotypic cultures with SFN (5, 10, and 15 μM) and cisplatin (10 μM). Immunofluorescence, cell viability, and protein analysis were performed to further analyze the protective mechanism of SFN on CIHL.

resultsSFN (30 mg/kg once a day) decreased cisplatin (7 mg/kg twice a day)-induced ABR threshold shifts and outer hair cell loss. CCK-8 assay showed that cisplatin (10 μM) reduced the viability of HEI-OC1 cells to 42%, and SFN had a dose-dependent protective effect. In cochlear organotypic cultures, we found that SFN (10 and 15 μM) increased cisplatin (10 μM)-induced myosin 7a

conclusionSFN prevented disruption of the HAT/HDAC balance, protecting against CIHL in rats.

Indexed as

Antineoplastic AgentsCisplatinAnimalsCell CountCiliaCochleaDose-Response Relationship, DrugEvoked Potentials, Auditory, Brain StemHair Cells, Auditory, OuterHearing LossHistone Deacetylase InhibitorsHistone DeacetylasesIsothiocyanatesRatsRats, WistarSulfoxidesAntineoplastic AgentsCisplatinHDAC7 protein, ratHDAC9 protein, ratHistone Deacetylase InhibitorsHistone DeacetylasesIsothiocyanatessulforaphaneSulfoxideshearing losshistone deacetylasehistone deacetylase inhibitorototoxicitysulforaphane

Identifiers

PMID34344210
PMCPMC8351026
OpenAlexW3193182243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.